

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 September 2024 (12.09.2024)



(10) International Publication Number
WO 2024/184206 A1

(51) International Patent Classification:

C07K 14/64 (2006.01) A61P 9/00 (2006.01)
A61K 38/22 (2006.01) A61K 38/00 (2006.01)

(21) International Application Number:

PCT/EP2024/055310

(22) International Filing Date:

01 March 2024 (01.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23160008.1 03 March 2023 (03.03.2023) EP

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; 151 85
Södertälje (SE).

(72) Inventor: **KE, Peng**; AstraZeneca UK Limited, 1 Francis
Crick Avenue, Cambridge Biomedical Campus, Cambridge
Cambridgeshire CB2 0AA (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Association 813, Eastbrook House, Shaftesbury Road,
CAMBRIDGE Cambridgeshire CB2 8BF (GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: PHARMACEUTICAL FORMULATION COMPRISING HETERODIMERIC RELAXIN FUSION PROTEINS AND
USES THEREOF




Fig. 25

(57) Abstract: The present disclosure relates to pharmaceutical formulations comprising heterodimeric Relaxin fusion polypeptides, in particular heterodimeric Relaxin 2 fusion polypeptides and uses thereof. Thus, the disclosure provides pharmaceutical formulations comprising Relaxin fusion polypeptides and kits comprising the same and uses of the same including methods of treatment. The pharmaceutical formulations of the disclosure may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*